Company intelligence / Profile preview

Zhejiang Lifang Pharmaceutical

Shaoxing (Shengzhou), Zhejiang, China

Ownership: Private
Employees: ~500
Development stage: Other

Overview

One of China’s leading manufacturers of oral cephalosporins and other generic APIs, with several cardiovascular and renal therapies marketed in China. No innovative clinical pipeline disclosed; portfolio is largely generic/commercialized

Therapeutic areas: NephrologyEndocrinologyInfectious DiseasesCardiovascularNeurology
Modalities: Small moleculeAntibiotic (mainly cephalosporins)APIPharmaceutical preparation
Industry: Biotech

Partnerships

Fresenius Kabi (JV)Guangyao Baiyun Mountainseveral Chinese pharma partners

Beyond the preview

Go deeper on Zhejiang Lifang Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhejiang Lifang Pharmaceutical.

Explore the full profile